» Articles » PMID: 32585672

TUBB3 Is Associated with High-Grade Histology, Poor Prognosis, P53 Expression, and Cancer Stem Cell Markers in Clear Cell Renal Cell Carcinoma

Overview
Journal Oncology
Specialty Oncology
Date 2020 Jun 26
PMID 32585672
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: βIII-Tubulin, encoded by the TUBB3 gene, is a microtubule protein. Several studies have shown that overexpression of TUBB3 is linked to poor prognosis and is involved in taxane resistance in some cancers.

Objective: The aim of this study was to analyze the expression and function of TUBB3 in clear cell renal cell carcinoma (ccRCC).

Methods: The expression of TUBB3 was determined using immuno-histochemistry in ccRCC specimens. The effects of TUBB3 knockdown on cell growth and invasion were evaluated in RCC cell lines. We analyzed the interaction between TUBB3, p53, cancer stem cell markers, and PD-L1.

Results: In 137 cases of ccRCC, immunohistochemistry showed that 28 (20%) of the ccRCC cases were positive for TUBB3. High TUBB3 expression was significantly correlated with high nuclear grade, high T stage, and N stage. A Kaplan-Meier analysis showed that high expression of TUBB3 was associated with poor overall survival after nephrectomy. In silico analysis also showed that high TUBB3 expression was correlated with overall survival. Knockdown of TUBB3 suppressed cell growth and invasion in 786-O and Caki-1 cells. High TUBB3 expression was associated with CD44, CD133, PD-L1, and p53 in ccRCC. We generated p53 knockout cells using the CRISPR-Cas9 system. Western blotting revealed that p53 knockout upregulated the expression of TUBB3.

Conclusion: These results suggest that TUBB3 may play an oncogenic role and could be a potential therapeutic target in ccRCC.

Citing Articles

Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screening.

Zhao D, Deshpande R, Wu K, Tyagi A, Sharma S, Wu S Neoplasia. 2024; 60:101100.

PMID: 39671912 PMC: 11699798. DOI: 10.1016/j.neo.2024.101100.


PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives.

Zhu Z, Jin Y, Zhou J, Chen F, Chen M, Gao Z Mol Cancer. 2024; 23(1):146.

PMID: 39014460 PMC: 11251344. DOI: 10.1186/s12943-024-02059-y.


Mass spectrometry-based proteomic analysis to characterize cisplatin induced early signaling events in head and neck squamous cell carcinoma.

Jain A, Ghose V, Munshi S, Bhat F, Dey G, Nanjappa V Mol Cell Oncol. 2024; 11(1):2328873.

PMID: 38487372 PMC: 10939151. DOI: 10.1080/23723556.2024.2328873.


Identification of alternative splicing associated with clinical features: from pan-cancers to genitourinary tumors.

Duan C, Zhang Y, Li L, Liu K, Yao X, Wu X Front Oncol. 2023; 13:1249932.

PMID: 37810965 PMC: 10557043. DOI: 10.3389/fonc.2023.1249932.


Quantitative Evaluation of Stem-like Markers of Human Glioblastoma Using Single-Cell RNA Sequencing Datasets.

He Y, Dossing K, Sloth A, He X, Rossing M, Kjaer A Cancers (Basel). 2023; 15(5).

PMID: 36900348 PMC: 10001303. DOI: 10.3390/cancers15051557.